RXRX · Recursion Pharmaceuticals, Inc. — research history

Recursion is an AI-native clinical-stage TechBio company with $654M cash and ~$72M debt. The stock has collapsed from its 52-week high of $7.18 to $3.23 (-55%), driven by collapsing revenue (Q1 2026: $6.5M vs $14.8M Q1 2025), accelerating cash burn (~320M/yr operating loss), and no meaningful insider buying. The only bullish signal is an analyst consensus target of $6.64 implying 106% upside, but that target was set before the Q2 revenue deterioration became evident. All recent insider activity (25 Form 4s reviewed) consists exclusively of: (1) pre-planned 10b5-1 sales by directors Borgeson ($110K), Bumpus ($15.5K), and Gibson (~$145K via conversions + sales); and (2) tax withholding surrenders on RSUs for CEO Khan and CFO Taylor — no discretionary open-market purchases of any kind from any officer or director. The June 4 AI pipeline update drove a 16% one-day spike that subsequently faded, suggesting limited sustained conviction. Next earnings Aug 5, 2026 is the primary near-term catalyst.

Recursion Pharmaceuticals is a clinical-stage AI-driven TechBio company with five programs in the clinic and >$500M received from pharma partnerships (Roche/Genentech, Sanofi). The investigation was triggered by a Form 4 cluster — however, upon reading every filing directly, ALL recent transactions are AUTOMATED SELLING under pre-established Rule 10b5-1 plans or RSU tax withholding. CEO Najat Khan sold $84K via 10b5-1; co-founder Blake Borgeson (director) sold ~$110K; director Namandje Bumpus sold ~$15.5K — all at market prices during a -25% YTD decline to near 52-week lows. There are zero open-market purchases from any insider in the past 90 days. The stock has negative forward P/E, no approved products, and revenue fell 56% YoY in FY2025 before recovering slightly Q1 2026. REC-4881 achieved Phase 2 success in FAP with FDA engagement ongoing — a genuine catalyst — but cash burn remains substantial (~$128M operating loss in Q1 alone) and the company is burning ~$300M+ annually against $655M of cash. The Form 4 cluster that triggered this investigation was entirely selling, not accumulation.

{"symbol":"RXRX","company":"Recursion Pharmaceuticals, Inc.","investigation_summary":"Recursion is a clinical-stage TechBio company that has decoded biology at scale using AI for drug discovery. The company achieved its first Phase 2 success with REC-4881 in familial adenomatous polyposis (FAP) — a disease with no approved pharmacotherapies — and has active FDA engagement on a potential registrati

The Form 4 cluster that triggered this investigation resolves to pre-planned sales (10b5-1) and tax withholding events — not open-market conviction purchases. No insider bought shares in the past 90 days. The stock has collapsed ~47% from its 52-week high ($7.18 → $3.80), hit a new 52-week low in May 2026, and is now bouncing on positive clinical updates for REC-1245 and Phase 2 success with REC-4881 (FAP). Cash runway extends to early 2028 at current burn. The company participates at Goldman Sachs Healthcare Conference June 9 — an event catalyst exists within the window. However, without any genuine open-market insider buys, the smart-money signal is neutral-to-slightly negative given coordinated selling via 10b5-1 plans.